Shattuck Labs, Inc.
Clinical-stage biotech developing novel biologic medicines for inflammatory & autoimmune diseases.
STTK | US
Overview
Corporate Details
- ISIN(s):
- US82024L1035
- LEI:
- Country:
- United States of America
- Address:
- 500 W. 5TH STREET, 78701 AUSTIN
- Website:
- https://www.shattucklabs.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Shattuck Labs, Inc. is a clinical-stage biotechnology company dedicated to developing novel biologic medicines for inflammatory and autoimmune diseases. The company leverages its expertise in state-of-the-art protein engineering and its deep understanding of the tumor necrosis factor (TNF) receptor superfamily to create specialized therapeutics. Shattuck's lead program, SL-325, is a potentially first-in-class monoclonal antibody antagonist of Death Receptor 3 (DR3). This therapeutic is designed to achieve a deep and durable blockade of the clinically validated TL1A/DR3 pathway for the treatment of Inflammatory Bowel Disease (IBD) and other immune-mediated conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Shattuck Labs, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Shattuck Labs, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Shattuck Labs, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
